dengue virus-1 #45az5 + autologous monocyte-derived lysate pulsed dendritic cells

**dengue virus-1 #45az5 + autologous monocyte-derived lysate pulsed dendritic cells** is a combination cellular immunotherapy investigational product. It consists of autologous dendritic cells derived from patient monocytes, which are pulsed (i.e., loaded or incubated) with lysates—cellular extracts—prepared from a dengue virus-1 isolate labeled as #45az5. The intent is to stimulate an immune response against Dengue virus-1 by presenting dengue antigens through potent antigen-presenting cells to the patient’s immune system. This approach is analogous to cancer vaccines using autologous monocyte-derived dendritic cells pulsed with tumor lysate; such therapies have shown ability to induce cellular immune responses, particularly strong T-cell responses, but their clinical effectiveness varies depending on disease and antigenic burden[4][5][6]. For dengue, this therapy would be considered experimental, likely targeting either prophylactic or therapeutic immunization in high-risk populations or for post-infection immune support.

Other names

dengue virus-1 #45az5 + autologous monocyte-derived lysate pulsed dendritic cells